Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Non-cash Items (2017 - 2025)

UroGen Pharma's Non-cash Items history spans 9 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 92.33% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, up 92.33%, while the annual FY2025 figure was $2.1 million, 92.33% up from the prior year.
  • Non-cash Items reached $2.1 million in Q4 2025 per URGN's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $5.1 million in Q4 2023 to a low of $1.1 million in Q4 2024.
  • Average Non-cash Items over 5 years is $2.5 million, with a median of $2.1 million recorded in 2025.
  • Peak YoY movement for Non-cash Items: crashed 84.08% in 2021, then surged 168.63% in 2023.
  • A 5-year view of Non-cash Items shows it stood at $2.1 million in 2021, then decreased by 11.15% to $1.9 million in 2022, then soared by 168.63% to $5.1 million in 2023, then tumbled by 78.72% to $1.1 million in 2024, then surged by 92.33% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Non-cash Items are $2.1 million (Q4 2025), $1.1 million (Q4 2024), and $5.1 million (Q4 2023).